SUVEN PHARMACEUTICALS Financial Statement Analysis
|
||
|
The Revenues of SUVEN PHARMACEUTICALS have decreased by -99.22% YoY .
The Earnings Per Share (EPS) of SUVEN PHARMACEUTICALS has decreased by -10.77 % YoY. |
||
SUVEN PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 543064|NSE : SUVENPHAR]
| Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
|---|---|---|---|---|---|
| Revenues | ₹1,051 Cr | ₹134,033 Cr | ₹1,320 Cr | ₹1,010 Cr | ₹834 Cr |
| Expenses | ₹646 Cr | ₹76,617 Cr | ₹739 Cr | ₹567 Cr | ₹449 Cr |
| Operating Profit (Excl OI) | ₹406 Cr | ₹57,416 Cr | ₹582 Cr | ₹443 Cr | ₹385 Cr |
| Other Income | ₹62 Cr | ₹4,636 Cr | ₹92 Cr | ₹14 Cr | ₹18 Cr |
| Interest | ₹7.45 Cr | ₹1,281 Cr | ₹8.53 Cr | ₹12 Cr | ₹23 Cr |
| Depreciation | ₹55 Cr | ₹4,799 Cr | ₹39 Cr | ₹32 Cr | ₹24 Cr |
| Profit Before Tax | ₹406 Cr | ₹55,973 Cr | ₹668 Cr | ₹468 Cr | ₹405 Cr |
| Profit After Tax | ₹300 Cr | ₹41,129 Cr | ₹454 Cr | ₹362 Cr | ₹317 Cr |
| Consolidated Net Profit | ₹300 Cr | ₹41,129 Cr | ₹454 Cr | ₹362 Cr | ₹317 Cr |
| Earnings Per Share (Rs) | ₹10.52 | ₹11.79 | ₹16.16 | ₹17.83 | ₹14.23 |
| PAT Margin (%) | 22.11 | 28.56 | 30.66 | 34.35 | 35.89 |
| ROE(%) | 14.20 | 15.87 | 25.21 | 33.52 | 35.78 |
| ROCE(%) | 18.44 | 21.22 | 33.41 | 45.92 | 40.76 |
| Total Debt/Equity(x) | 0.05 | 0.02 | 0.04 | 0.06 | 0.12 |
Key Financials |
||
| Market Cap | : | ₹ 11,210.2 Cr |
| Revenue (TTM) | : | ₹ 2,051.5 Cr |
| Net Profit(TTM) | : | ₹ 180.5 Cr |
| EPS (TTM) | : | ₹ 4.7 |
| P/E (TTM) | : | 62.1 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| SUVEN PHARMACEUTICALS | -0.6% | -12.9% | -75.6% |
| SUN PHARMACEUTICAL INDUSTRIES | 3.6% | 7% | 15.3% |
| DIVIS LABORATORIES | 1.1% | 5.8% | 14.8% |
| CIPLA | 1.6% | 0.2% | -5.4% |
| TORRENT PHARMACEUTICALS | 1.9% | 12.3% | 49.2% |
| DR REDDYS LABORATORIES | 1.8% | 5.9% | 14.8% |
| MANKIND PHARMA | 1.5% | 8.7% | -5% |
| ZYDUS LIFESCIENCES | 2.9% | 4% | 4.2% |
| LUPIN | 1.6% | 8% | 17.9% |
SUVEN PHARMACEUTICALS Revenues
[BOM: 543064|NSE : SUVENPHAR]
| Y-o-Y | -99.22 % |
| 5 Yr CAGR | 5.97 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹1,051 Cr | -99.22 | |
| Mar2024 | ₹134,033 Cr | 10,052.30 | |
| Mar2023 | ₹1,320 Cr | 30.75 | |
| Mar2022 | ₹1,010 Cr | 21.10 | |
| Mar2021 | ₹834 Cr | - | |
SUVEN PHARMACEUTICALS Operating Profit
[BOM: 543064|NSE : SUVENPHAR]
| Y-o-Y | -99.29 % |
| 5 Yr CAGR | 1.34 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹406 Cr | -99.29 | |
| Mar2024 | ₹57,416 Cr | 9,770.06 | |
| Mar2023 | ₹582 Cr | 31.31 | |
| Mar2022 | ₹443 Cr | 15.14 | |
| Mar2021 | ₹385 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -9.90 % |
| 5 Yr CAGR | -4.37 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 38.6% | -9.90 | |
| Mar2024 | 42.84% | -2.77 | |
| Mar2023 | 44.06% | 0.43 | |
| Mar2022 | 43.87% | -4.94 | |
| Mar2021 | 46.15% | - | |
SUVEN PHARMACEUTICALS Profit After Tax
[BOM: 543064|NSE : SUVENPHAR]
| Y-o-Y | -99.27 % |
| 5 Yr CAGR | -1.35 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹300 Cr | -99.27 | |
| Mar2024 | ₹41,129 Cr | 8,963.15 | |
| Mar2023 | ₹454 Cr | 25.24 | |
| Mar2022 | ₹362 Cr | 14.30 | |
| Mar2021 | ₹317 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -22.58 % |
| 5 Yr CAGR | -11.41 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 22.11 % | -22.58 | |
| Mar2024 | 28.56 % | -6.85 | |
| Mar2023 | 30.66 % | -10.74 | |
| Mar2022 | 34.35 % | -4.29 | |
| Mar2021 | 35.89 % | - | |
SUVEN PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 543064|NSE : SUVENPHAR]
| Y-o-Y | -10.77 % |
| 5 Yr CAGR | -7.27 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹11 | -10.77 | |
| Mar2024 | ₹12 | -27.04 | |
| Mar2023 | ₹16 | -9.37 | |
| Mar2022 | ₹18 | 25.30 | |
| Mar2021 | ₹14 | - | |
SUVEN PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 543064|NSE : SUVENPHAR]
| Y-o-Y | -13.10 % |
| 5 Yr CAGR | -17.99 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 18.44% | -13.10 | |
| Mar2024 | 21.22% | -36.49 | |
| Mar2023 | 33.41% | -27.24 | |
| Mar2022 | 45.92% | 12.66 | |
| Mar2021 | 40.76% | - | |
SUVEN PHARMACEUTICALS Share Price vs Sensex
| Current Share Price | : | ₹293.0 |
| Current MarketCap | : | ₹ 11,210.2 Cr |
| Updated EOD on | : | Mar 11,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SUVEN PHARMACEUTICALS | -0.6% |
-12.9% |
-75.6% |
| SENSEX | -2.9% |
-8% |
5.3% |
SUVEN PHARMACEUTICALS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE 500 SHARIAH | 4.3% | 4.3% | 1.1% |
| BSE HEALTHCARE | 1.9% | 4.7% | 13.9% |
| BSE SMALLCAP SELECT INDEX | 0.4% | -3.6% | 14.5% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MIDSMALL HEALTHCARE | 2.2% | 5.8% | 16.2% |
| NIFTY SMALLCAP 250 | 0.5% | -3.4% | 10.2% |
| NIFTY500 MULTICAP INDIA MANUFACTURING 50:30:20 | 0.2% | -1.7% | 18.9% |
| NIFTY 500 EQUAL WEIGHT | -0.2% | -4.3% | 11.9% |
| NIFTY MIDSMALLCAP 400 | -0.4% | -4.4% | 14.6% |
You may also like the below Video Courses
FAQ about SUVEN PHARMACEUTICALS Financials
How the annual revenues of SUVEN PHARMACEUTICALS have changed ?
The Revenues of SUVEN PHARMACEUTICALS have decreased by -99.22% YoY .
How the Earnings per Share (EPS) of SUVEN PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of SUVEN PHARMACEUTICALS has decreased by -10.77 % YoY .
Check out Intrinsic Value of Peers of SUVEN PHARMACEUTICALS
Compare Stock Analytics of Peers of SUVEN PHARMACEUTICALS
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
